Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 8—August 2021

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children

Corinne LevyComments to Author , Naim Ouldali, Emmanuelle Varon, Stéphane Béchet, Stéphane Bonacorsi, and Robert Cohen
Author affiliations: Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France (C. Levy, N. Ouldali, S. Béchet, R. Cohen); Groupe de Pathologie Infectieuse Pédiatrique, Paris, France (C. Levy, N. Ouldali, E. Varon, S. Bonacorsi, R. Cohen); Université Paris Est, IMRB-GRC GEMINI, Créteil (C. Levy, E. Varon, R. Cohen); Centre Hospitalier Intercommunal de Créteil, Créteil (C. Levy, E. Varon, R. Cohen); Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France (C. Levy, R. Cohen); Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, ECEVE INSERM UMR 1123, Paris (N. Ouldali, S. Bonacorsi); Université de Paris, IAME, UMR 1137, INSERM, Paris (S. Bonacorsi)

Main Article


Comparison of pneumococcal serotypes in children <24 mo of age in Israel, 2015–2017, and France, 2015–2018*

Serotypes Cases of invasive pneumococcal disease, no. (%)
Israel France
216 (100.0)
113 (100.0)
PCV13 serotypes 22 (10.2) 5 (4.4)
22F 8 (3.7) 8 (7.1)
23 (10.6)
5 (4.4)
PCV15 serotypes† 53 (24.5) 18 (15.9)
8 2 (0.9) 2 (1.8)
10A 8 (3.7) 11 (9.7)
11A 3 (1.4) 2 (1.8)
12F 58 (26.9) 1 (0.9)
10 (4.6)
13 (11.5)
PCV20 serotypes‡
134 (62.0)
47 (41.6)
Non-VT20 82 (38.0) 66 (58.4)
7 (3.2)
31 (27.4)
112 (51.9)
42 (37.2)
Non-PCV13 194 (89.8) 108 (95.6)

*Non-VT20, serotypes in PCV20; PCV13, 13-valent PCV; PCV15, 15-valent PCV; PCV20, 20-valent PCV; PCV, pneumococcal conjugate vaccine; VT20–13, vaccine types in PCV20 but not PCV13. †Comprises PCV13 serotypes as well as 22F and 33F. ‡Comprises PCV15 serotypes as well as 8, 10A, 11A, 12F, and 15B/C.

Main Article

Page created: May 17, 2021
Page updated: July 19, 2021
Page reviewed: July 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.